Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Next-generation lung cancer pathology: Development and validation of diagnostic and prognostic algorithms.
Kludt C, Wang Y, Ahmad W, Bychkov A, Fukuoka J, Gaisa N, Kühnel M, Jonigk D, Pryalukhin A, Mairinger F, Klein F, Schultheis AM, Seper A, Hulla W, Brägelmann J, Michels S, Klein S, Quaas A, Büttner R, Tolkach Y. Kludt C, et al. Among authors: bragelmann j. Cell Rep Med. 2024 Sep 17;5(9):101697. doi: 10.1016/j.xcrm.2024.101697. Epub 2024 Aug 22. Cell Rep Med. 2024. PMID: 39178857 Free PMC article.
Blocking the angiopoietin-2-dependent integrin β-1 signaling axis abrogates small cell lung cancer invasion and metastasis.
Meder L, Orschel CI, Otto CJ, Koker M, Brägelmann J, Ercanoglu MS, Dähling S, Compes A, Selenz C, Nill M, Dietlein F, Florin A, Eich ML, Borchmann S, Odenthal M, Blazquez R, Hilberg F, Klein F, Hallek M, Büttner R, Reinhardt HC, Ullrich RT. Meder L, et al. Among authors: bragelmann j. JCI Insight. 2024 May 22;9(10):e166402. doi: 10.1172/jci.insight.166402. JCI Insight. 2024. PMID: 38775153 Free PMC article.
CDK9 inhibition as an effective therapy for small cell lung cancer.
Valdez Capuccino L, Kleitke T, Szokol B, Svajda L, Martin F, Bonechi F, Krekó M, Azami S, Montinaro A, Wang Y, Nikolov V, Kaiser L, Bonasera D, Saggau J, Scholz T, Schmitt A, Beleggia F, Reinhardt HC, George J, Liccardi G, Walczak H, Tóvári J, Brägelmann J, Montero J, Sos ML, Őrfi L, Peltzer N. Valdez Capuccino L, et al. Among authors: bragelmann j. Cell Death Dis. 2024 May 20;15(5):345. doi: 10.1038/s41419-024-06724-4. Cell Death Dis. 2024. PMID: 38769311 Free PMC article.
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
Malchers F, Nogova L, van Attekum MH, Maas L, Brägelmann J, Bartenhagen C, Girard L, Bosco G, Dahmen I, Michels S, Weeden CE, Scheel AH, Meder L, Golfmann K, Schuldt P, Siemanowski J, Rehker J, Merkelbach-Bruse S, Menon R, Gautschi O, Heuckmann JM, Brambilla E, Asselin-Labat ML, Persigehl T, Minna JD, Walczak H, Ullrich RT, Fischer M, Reinhardt HC, Wolf J, Büttner R, Peifer M, George J, Thomas RK. Malchers F, et al. Among authors: bragelmann j. J Clin Invest. 2023 Nov 1;133(21):e170217. doi: 10.1172/JCI170217. J Clin Invest. 2023. PMID: 37606995 Free PMC article.
Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.
Glaser M, Rasokat A, Prang D, Nogova L, Wömpner C, Schmitz J, Bitter E, Terjung I, Eisert A, Fischer R, John F, von Levetzow C, Michels S, Riedel R, Ruge L, Scharpenseel H, Siebolts U, Merkelbach-Bruse S, Buettner R, Brägelmann J, Wolf J, Scheffler M. Glaser M, et al. Among authors: bragelmann j. Lung Cancer. 2023 Oct;184:107344. doi: 10.1016/j.lungcan.2023.107344. Epub 2023 Aug 12. Lung Cancer. 2023. PMID: 37579577 Free article.
KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.
Arolt C, Dugan M, Wild R, Richartz V, Holz B, Scheel AH, Brägelmann J, Wagener-Ryczek S, Merkelbach-Bruse S, Wolf J, Buettner R, Catanzariti L, Scheffler M, Hillmer AM. Arolt C, et al. Among authors: bragelmann j. J Thorac Oncol. 2023 Nov;18(11):1550-1567. doi: 10.1016/j.jtho.2023.07.016. Epub 2023 Jul 18. J Thorac Oncol. 2023. PMID: 37473958 Free article.
Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer.
Müller N, Lorenz C, Ostendorp J, Heisel FS, Friese UP, Cartolano M, Plenker D, Tumbrink H, Heimsoeth A, Baedeker P, Weiss J, Ortiz-Cuaran S, Büttner R, Peifer M, Thomas RK, Sos ML, Berg J, Brägelmann J. Müller N, et al. Among authors: bragelmann j. Cancer Res. 2023 Aug 1;83(15):2471-2479. doi: 10.1158/0008-5472.CAN-22-2605. Cancer Res. 2023. PMID: 37289018
57 results